李川川

发布时间：2026-06-09浏览次数：10

教师基本信息：

姓名：李川川

职称：助理教授（A）

电子邮箱：lichuanchuan@fudan.edu.cn

办公地点：生命科学楼C-623

办公电话：021-31246624，021-31246625

研究方向：肿瘤靶向药和临床转化

个人简介：

李川川，助理教授（A），博士生导师。2017年于中国科学院分子细胞科学卓越创新中心（前“中国科学院生物化学与细胞生物学研究所”）获博士学位，2017年6月-2023年10月于纽约纪念斯隆凯特琳癌症中心（MSKCC）从事博士后研究。2024年入职复旦大学生命科学学院任助理教授（A），复杂性状的遗传调控全国重点实验室研究组长，“十五五”生物技术药物与疫苗研制项目团队成员。主持多项国自然项目。入选国家级青年项目和上海市领军人才项目。

代表性工作：

系统解析了癌症驱动分子KRAS突变体靶向药在抗肿瘤方面的分子机理。揭示了KRAS失活的新机制，为未来开发靶向KRAS突变体抑制剂提供了全新的思路。Science同期配发了KRAS发现者Channing J. Der教授的专题评述。迄今以第一作者（含共同）在Science，Nature Communications、Nature Immunology等国际学术期刊发表研究论文。

授课情况：《细胞生物学(荣誉课程)》，《细胞生物学》

招生专业：细胞生物学

Personal Introduction

I am a Principal Investigator at the School of Life Sciences, Fudan University. I received my Ph.D. from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and subsequently conducted postdoctoral research at Memorial Sloan Kettering Cancer Center (MSKCC), where I focused on KRAS-targeted therapeutics and cancer signaling. My research has contributed to the understanding of KRAS biology and targeted therapy, including the discovery of RGS3 as a mutant-tolerant KRAS GTPase-activating protein that modulates KRAS signaling and sensitivity to KRAS inhibitors. My work has been published in leading journals including Science, Nature Immunology, Nature Communications, and others. My laboratory aims to bridge fundamental cancer biology and translational drug discovery to develop next-generation therapeutic strategies for KRAS-mutant cancers.

Research Focus

Our laboratory is dedicated to understanding the molecular mechanisms underlying KRAS-driven cancers and developing innovative therapeutic strategies for their treatment. We integrate cancer biology, chemical biology, structural biology, and computational approaches to investigate oncogenic KRAS signaling, drug resistance, and intercellular communication.

Current research interests include:

  • Molecular mechanisms regulating KRAS signaling and nucleotide      cycling

  • Development of mutant-selective inhibitors

  • Mechanisms of resistance to KRAS-targeted therapies

  • AI-assisted drug discovery and precision oncology

  • Translational studies toward novel anti-cancer therapeutics

Admission Specialties & Research Projects

Admission Specialties

We welcome highly motivated undergraduate, master's, doctoral, and postdoctoral researchers with backgrounds in:

  • Molecular      and Cell Biology

  • Biochemistry      and Structural Biology

  • Cancer      Biology

  • Chemical      Biology and Medicinal Chemistry

  • Artificial      Intelligence for Drug Discovery

  • Biomedical      Engineering and Translational Medicine

Research Projects

Students joining the laboratory may participate in projects including:

  1. KRAS      signaling dynamics and nucleotide cycling mechanisms

  2. Discovery      of novel KRAS-targeted inhibitors

  3. Mechanisms      of adaptive resistance to KRAS-targeted therapies

  4. AI-guided      design of targeted anti-cancer therapeutics

  5. Translational      development of next-generation cancer therapeutics

代表性论文和论著：

1.           Li M*, Zhou Y*, Qiao T, Bai Q, Li C. Unlocking drug sensitivity in KRAS. 

Scientia Sinica Vitae.2026;56(4):863–874.（复旦大学生命科学学院100周年专题）

2.           Nie P, Cao Z, Yu R, Dong C, Zhang W, Meng Y, Zhang H, Pan Y, Tong Z, Jiang X, Wang S, Zhu M, Han Y, Wang W, Zhang Y, Tan L, Li C, Xu Y, An L, Li B, Jiao S, Zhou Z. Targeting p97–Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity.

Nature Immunology. 2024 Sep;25(9):1623–1636.

3.           Jiao S*, Li C*, Guo F*, Zhang J, Zhang H, Cao Z, Wang W, Bu W, Lin M, Lü J, Zhou Z SUN1/2 controls macrophage polarization via modulating nuclear size and stiffness

Nature Communications. 2023 Oct 12;14(1):6416.

4.           Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, Tomlinson A, Choy TJ, Wang Z, Sang B, Pourfarjam Y, Lucas J, Cuevas-Navarro A, Ayala-Santos C, Vides A, Li C, Marquez A, Zhong M, Vemulapalli V, Weller C, Gould A, Whalen DM, Salvador A, Milin A, Saldajeno-Concar M, Dinglasan N, Chen A, Evans J, Knox JE, Koltun ES, Singh M, Nichols R, Wildes D, Gill AL, Smith JAM, Lito P.

Science. 2023 Aug 18;381(6659):794-799.0

5.           Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Nature. 2023 Jul;619(7968):160-166

6.           Chuanchuan Li, Alberto Vides, Dongsung Kim, Jenny Y Xue, Yulei Zhao, Piro Lito The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.

Science. 2021 Oct 8;374(6564):197-201.

7.           Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with resistance to KRAS(G12C) inhibition

Nature. 2021 Nov;599(7886):679-683.

8.           Xue J, Zhao Y, Arono J, Mai TT, Vides A, Qeri B, Kim D, Li C, de Stanc E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.

Nature. 2020 Jan;577(7790):421-425.

9.           Jiao S, Guan J, Chen M, Wang W, Li C, Wang Y, Cheng Y, Zhou Z. Targeting IRF3 as a YAP agonist therapy against gastric cancer.

J Exp Med. 2018 Feb 5;215(2):699-718. 

10.        Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L, Zhou Z. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.

Nature Communications. 2017 Jan 4;8:14058.

11.        Shi Jiao＊, Zhen Zhang＊, Chuanchuan Li＊, Min Huang, Zhubing Shi, Yanyan Wang, Xiaomin Song, Heng Liu, Chunyang Li, Min Chen, Wenjia Wang, Yun Zhao, Zhengfan Jiang, Hongyan Wang, Catherine CL Wong, Chen Wang, Zhaocai Zhou. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor molecule TRAF6.

Nature Immunology, 2015, 16: 246-257

12.        Qian Hao, Shi Jiao, Zhubing Shi, Chuanchuan Li, Xia Meng, Zhen Zhang, Yanyan Wang, Xiaomin Song, Wenjia Wang, Rongguang Zhang, Yun Zhao, Catherine CL Wong, Zhaocai Zhou. A Non-canonical Role of the p97 Complex in RIG-I Antiviral Signaling.

EMBO J, 2015, doi: e201591888

13.        Zhubing Shi, Zhen Zhang, Zhenzhen Zhang, Yicui Wang, Chuanchuan Li，Xin Wang, Feng He, Lina Sun, Shi Jiao, Weiyang Shi, Zhaocai Zhou. Structural Insights into Mitochondrial Antiviral-Signaling Protein (MAVS)-Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) Signaling.

J Biol Chem. 2015, 290: 26811-20

14.        Zhao Zhang, Yanyan Wang, Chuanchuan Li, Zhubing Shi, Qiao Hao, Wenjia Wang, Xiaomin Song, Yun Zhao, Shi Jiao, Zhaocai Zhou. The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-κB Signaling via Partial Degradation of the NF-κB Subunit p100.

J Biol Chem, 2015, 290: 19558-68

15.        Chuanchuan Li＊, Miao Feng＊, Zhubing Shi, Qian Hao, Xiaomin Song, Wenjia Wang, Yun Zhao, Shi Jiao, Zhaocai Zhou. Structural and Biochemical Insights into the Activation Mechanisms of Germinal Center Kinase OSR1.

J Biol Chem, 2014, 289: 35969-35978.